Development of inhibitors of protein-protein interactions through REPLACE: Application to the design and development NON-ATP competitive CDK inhibitors

Journal of Visualized Experiments

Volumn 2015, Issue 104, 2015, Pages

  Premnath, Padmavathy Nandha ^a   Craig, Sandra ^a   McInnes, Campbell ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cyclin binding groove; Cyclin dependent kinase inhibitor; Drug; Drug discovery; Issue 104; Molecular biology; Protein protein interactions

Indexed keywords

EID: 84946426560     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/52441     Document Type: Article

References (23)

1. Andrews, M. J. et al. REPLACE: a strategy for iterative design of cyclin-binding groove inhibitors. Chembiochem. 7, 1909-1915, doi: 10.1002/ cbic.200600189 (2006).
2. Liu, S. et al. Optimization of Non-ATP Competitive CDK/Cyclin Groove Inhibitors through REPLACE-Mediated Fragment Assembly. J Med Chem. 56, 1573-1582, doi: 10.1021/jm3013882 (2013).
3. McInnes, C. in Annual Reports in Medicinal Chemistry. Vol. 47 (ed M Bernstein P; Desai) Ch. 29, 459-474 Elsevier, (2012).
4. Bower, J. F., & Pannifer, A. Using fragment-based technologies to target protein-protein interactions. Curr Pharm Des. 18, 4685-4696 (2012).
5. Makley, L. N., & Gestwicki, J. E. Expanding the number of 'druggable' targets: non-enzymes and protein-protein interactions. Chemical biology, & drug design. 81, 22-32, doi: 10.1111/cbdd.12066 (2013).
6. Walensky, L. D., & Bird, G. H. Hydrocarbon-Stapled Peptides: Principles, Practice, and Progress. J Med Chem., doi: 10.1021/jm4011675 (2014).
7. Shapiro, G. I. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 24, 1770-1783, doi: 10.1200/ JCO.2005.03.7689 (2006).
8. Thais, M., Sielecki, J. F. B., Pamela A. Enfield, & George l. Trainor. Cyclin dependant kinase inhibitors: Useful targets in cell cycle regulation. Journal of medicinal chemistry. 43 1-18 (2000).
9. Morphy, R. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem. 53, 1413-1437, doi: 10.1021/jm901132v (2010).
10. Chen, Y. N. et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 96, 4325-4329 (1999).
11. Orzaez, M., Gortat, A., Mondragon, L., Bachs, O., & Perez-Paya, E. ATP-noncompetitive inhibitors of CDK-cyclin complexes. ChemMedChem. 4, 19-24, doi: 10.1002/cmdc.200800185 (2009).
12. Kontopidis, G. et al. Insights into cyclin groove recognition: complex crystal structures and inhibitor design through ligand exchange. Structure. 11, 1537-1546 (2003).
13. McInnes, C., Andrews, M. J., Zheleva, D. I., Lane, D. P., & Fischer, P. M. Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit. Current medicinal chemistry. Anti-cancer agents. 3, 57-69 (2003).
14. Premnath, P. N. et al. Fragment based discovery of arginine isosteres through REPLACE: towards non-ATP competitive CDK inhibitors. Bioorganic, & medicinal chemistry. 22, 616-622, doi: 10.1016/j.bmc.2013.10.039 (2014).
15. Venkatachalam, C. M., Jiang, X., Oldfield, T., & Waldman, M. LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. J Mol Graph Model. 21, 289-307 (2003).
16. Mendoza, N. et al. Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth. Cancer Res. 63, 1020-1024 (2003).
17. Denizot, F., & Lang, R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 89, 271-277 (1986).
18. Zheleva, D. I. et al. Highly potent p21(WAF1)-derived peptide inhibitors of CDK-mediated pRb phosphorylation: delineation and structural insight into their interactions with cyclin A. The journal of peptide research: official journal of the American Peptide Society. 60, 257-270 (2002).
19. Andrei A. Ivanov, F. R. K., and Haian Fu. Targeting protein–protein interactions as an anticancer strategy. Trends in Pharmacological Sciences. 34 (2013).
20. Thayer, A. M. Improving peptides. Chemical and Engineering News. 89, 13-20 (2011).
21. Yin, H. A. H., A.D. Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem. Int. Ed. Engl. 44, 4130-4163 (2005).
22. Jubb, H., Higueruelo, A. P., Winter, A., & Blundell, T. L. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol Sci. 33, 241-248, doi: 10.1016/j.tips.2012.03.006 (2012).
23. Cannon, J.B. Pharmaceutics and drug delivery aspects of heme and porphyrin therapy. J Pharm Sci.82, 435-446 (1993).